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Abstract 
 
All but thirteen mammalian mitochondrial proteins are encoded by the nuclear genome, 
translated in the cytosol and then imported into the mitochondria. For a significant 
proportion of the mitochondrial proteins, import is coupled with the cleavage of a 
presequence called the transit peptide, and the formation of a new N-terminus. 
Determination of the neo N-termini has been investigated by proteomic approaches in 
several systems, but generally in a static way in order to compile as many N-termini as 
possible. In the present study, we have investigated how the mitochondrial proteome 
and N-terminome react to chemical stimuli that alter mitochondrial metabolism, namely 
zinc ions and rapamycin. To this end, we have used a strategy that analyzes both 
internal and N-terminal peptides in a single run, the dN-TOP approach. We used these 
two very different stressors to sort out what could be a generic response to stress and 
what is specific to each of these stressors. Rapamycin and zinc induced fairly different 
changes in the mitochondrial proteome. However, convergent changes to key 
mitochondrial enzymatic activities such as pyruvate dehydrogenase, succinate 
dehydrogenase and citrate synthase were observed for both treatments. Other 
convergent changes were seen in components of the N-terminal processing system and 
mitochondrial proteases. Investigations into the generation of neo N-termini in 
mitochondria showed that the processing system is robust, as indicated by the lack of 
change in neo N-termini under the conditions tested. Detailed analysis of the data 
revealed that zinc caused a slight reduction  in the efficiency of the N-terminal trimming 
system and that both treatments increased the degradation of mitochondrial proteins.  
In conclusion, the use of this combined strategy allowed a detailed analysis of the 
dynamics of the mitochondrial N-terminome in response to treatments which impact the 
mitochondria.  
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Introduction 
 
Organellar proteomics and especially mitochondrial proteomics are  almost as old as 
proteomics itself;  the first primitive draft of a human mitochondrial proteome was 
published only a few years after the word "proteomics" was coined (1). Mitochondrial 
proteomics has been used over the years for numerous applications (reviewed in 
(2)), such as the elucidation of the repertoire of mitochondrial proteins (e.g. in (3-6)). 
The approach has been refined to investigate the events that occur during protein 
import into the mitochondria. Almost all mitochondrial proteins are encoded in the 
nuclear DNA and imported into the mitochondria by a complex system (reviewed in 
(7-9)). In the case of at least half of the mitochondrial proteins, a transit peptide is 
cleaved during import, generating a new N-terminus. Therefore, N-terminomics 
approaches have been used to characterize the new N-termini in various organisms, 
from yeast to mammals (10-12). These studies have shown that besides the major 
mitochondrial processing peptidase that cleaves the transit peptide, the system 
includes aminopeptidases that trim the N-terminal end to create ragged termini and 
stabilize the proteins (10,13).  
Mitochondrial proteomics has also been used to investigate the modulations of the 
mitochondrial proteome in response to various biological situations, ranging from 
alterations of mitochondrial DNA (14,15) to various physiopathological situations 
such as aging (16-18), exposure to ionizing radiations (19), metal toxicity (20) and 
various metabolic (21-25) and iatrogenic (21, 26-29) perturbations.  
 
While determination of the neo-N-termini of mitochondrial proteins is still an active 
research field (10-12), nothing is yet known about the robustness of the 
mitochondrial protein processing system under conditions of mitochondrial stress, 
particularly non-lethal stress. It is not known, for example, whether errors occur in 
the precursor cleavage during stress, or how the other components of the 
mitochondrial protein processing system behave in such conditions.  
 
In this context, the aim of this study was to investigate the impact of sub-lethal doses 
of two known mitochondrial stressors, namely rapamycin and zinc, on human 
mitochondria. These two stressors were chosen as they act via different mechanisms 
and therefore allow determining whether the effects on the mitochondrial proteome 
and/or the processing system could be stress-generic or agent specific.  
On the one side, zinc is both a trace element essential for the proper functioning of 
the immune system (30,31) ) and a toxic element at high doses, causing for example 
the metal fume fever (32,33). The zinc ion has a strong affinity to sulfur and binds to 
glutathione (34) and to cysteine residues in protein active sites (35,36). This can 
result in the inhibition of key metabolic enzymes, ranging from glyceraldehyde 
phosphate dehydrogenase to mitochondrial enzymes (37-39). Interestingly, zinc 
toxicity is at least partly reversed by supplementation with metabolic end-products 
such as pyruvate and/or oxaloacetate (40-45). Thus, zinc toxicity is linked to 
metabolic dysfunction and with a clear involvement of the  mitochondria.  
 
On the other side, the drug rapamycin has a known strong impact on mitochondrial 
function. Its effects on the organelle have been described from the very beginning of 
its description (46) and refined over time  (47,48). Proteomics has contributed to the 
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understanding of its effects (49).  
 
To probe the effects of these two mitochondrial stressors on the mitochondrial 
proteome, as well as their impact on the mitochondrial protein processing system. 
The previously-described combined shotgun proteomics and N-terminomics 
approach afforded by the doublet N-terminal oriented (dN-TOP) strategy (50) was 
utilized in the present study.  
 
 
Materials and methods 
 
Cell culture 
 
The U937 cells were grown in suspension in RPMI1640 medium supplemented with 
10% fetal bovine serum and 10mM Hepes pH 7.5 buffer. Small-scale cultures  were 
carried out in 75cm2 or 175 cm2 flasks (culture volumes were 25 mL or 60 mL 
respectively) and used for targeted assays such as mitochondrial potential or 
enzyme activities. Large-scale cultures for mitochondrial preparations were carried 
out in 1 liter spinner bottles. Cells were grown to a density of 500,000 cells/mL and 
then treated with either 10nM rapamycin or 100µM zinc acetate. Both treatments 
induced <20% cell death, as determined by dye exclusion. All experiments were 
carried out on three independent cultures.  
 
Mitochondrial transmembrane potential measurement 
 
The mitochondrial transmembrane potential was assessed by Rhodamine 123 
uptake. Cells were incubated with 80 nM Rhodamine 123  for 30 minutes at 37°C in 
the incubator,  then rinsed twice in cold glucose (1 mg/ml) in PBS and harvested in 
cold glucose (1 mg/ml) - PBS with propidium iodide (1 µg/ml). The mitochondrial 
potential of cells was analyzed by flow cytometry on a FACScalibur instrument 
(Beckton Dickinson, Franklin Lakes, NJ). Dead cells (propidium positive) were 
excluded from analysis. A low rhodamine concentration (80 nM) was used to avoid 
intramitochondrial fluorescence quenching, which would result in a poor estimation of 
the mitochondrial potential (51) 
. 
Isolation of mitochondria  
 
Mitochondria were isolated as described in (52). Briefly, cells were harvested, rinsed 
three times in PBS and re-suspended in a ten-fold pellet volume of hypotonic buffer 
(10 mM Hepes-NaOH pH 7.5, 2 mM MgCl2, 1 mM EGTA, 50 mM KCl). After 10 
minutes on ice, cells were lysed with ten strokes of a Dounce homogenizer (tight 
pestle). A volume of 2 M sucrose equivalent to one-tenth that of buffer was added, 
and the mixture homogenized with two additional strokes. The suspension was 
centrifuged at 1000 g for 5 minutes to pellet the nuclei, unbroken cells and debris. 
The supernatant was collected then centrifuged at 7000 g for 10 minutes to pellet the 
mitochondria. The mitochondrial pellet was re-suspended in washing buffer (10 mM 
Hepes-NaOH pH 7.5, 2 mM MgCl2, 250 mM sucrose) and centrifuged at 7000 g for 
10 minutes. The protein concentration of the mitochondrial suspension was  
determined by a dye-binding assay (53) and the extracts were aliquoted and stored 
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at -80°C until use. This protocol afforded the best compromise between yield and 
purity (11).  
 
 
Experimental Design and Statistical Rationale 
 
Each rapamycin- and zinc acetate-treated cell culture was performed in biological 
triplicate (n=3). In parallel, three independent cell cultures underwent no treatment to 
generate control samples. Each sample was processed as described below and 
measured three times by mass spectrometry (MS), resulting in a total of 27 analyses.  
 
Proteomics analysis and dN-TOP strategy  
  
Sample preparation. The protocol used in the present study was adapted from 
previous work (11) and (52). Briefly, aliquots containing  400 µg of mitochondria-
enriched protein extract was taken for each sample. Aliquots were centrifuged at 
10,000g for 20 minutes and at 20,000g for 5 minutes at 4°C. The mitochondria were 
re-suspended in labeling buffer (50 mM Tris-HCl, 8 M urea, 2 M thiourea, 1% SDS, 
pH 8.2), reduced by incubating with 5 mM tributylphosphine (TBP) for 1 h and 
alkylated by incubating with 50 mM iodoacetamide  for  1 h at room temperature. An 
equimolar solution of 100  mM light and heavy N-
succinimidyloxycarbonylmethyl)tris(2,4,6-trimethoxyphenyl)phosphonium bromide 
(TMPP) 80% acetonitrile (ACN), 200:1 reagent:protein molar ratio was added, and 
the resulting solution incubated for 1h with shaking. Any residual derivatizing reagent 
was quenched by incubating with a solution of 0.1M hydroxylamine at room 
temperature for 1 h. Glycerol (10%) and bromophenol blue (1%) were added to the 
samples and stacking gel bands  prepared for 50 µg of each sample replicate. 
Stacking gel bands were excised, cut, in-gel reduced (using 10mM dithiothreitol in 
25mM NH4HCO3), alkylated (using 55mM iodoacetamide in 25mM NH4HCO3), and 
the proteins digested overnight using modified porcine trypsin (Promega, Madison, 
WI, USA) at 37 °C. Tryptic peptides were extracted using 60% ACN in 0.1% formic 
acid. After vacuum centrifugation, tryptic peptides were resuspended in 190 µl of 
0.1% formic acid (FA) in water. 
 
Nano-LC-MS/MS analysis. Nano-LC-MS/MS analysis was performed on a 
nanoAcquity UPLC device (Waters, Milford, MA, USA) coupled to a Q-Exactive Plus 
mass spectrometer (Thermo Fisher Scientific, Bremen, Germany). The solvents 
consisted of 0.1% FA in H2O (solvent A) and 0.1% FA in ACN (solvent B). Sample 
volumes of 2 µL  were loaded onto a Symmetry C18 precolumn (20 mm x 180 µm, 5 
µm diameter particles; Waters, Milford, MA) over 3 min at 5 µL/min with 1% solvent 
B. Peptides were eluted on an Acquity UPLC BEH130 C18 column (250 mm x 75 
µm, 1.7 µm particles; Waters, Milford, MA) at 450 nL/min with the following gradients 
of solvent B: linear from 1% to 20 % in 48 min, linear from 20% to 40% in 37 min, up 
to 90% in 1 min, isocratic at 90% for 8 min, down to 1% in 1 min, isocratic at 1% for 
25 min.  
The Q-Exactive Plus was operated in data-dependent acquisition mode by 
automatically switching between full MS and consecutive MS/MS acquisitions. Full-
scan MS spectra were collected from 300-1,800 m/z at a resolution of 70,000 at 200 
m/z with an automatic gain control target fixed at 3.106 ions and a maximum injection 
time of 50 ms. The top 10 precursor ions with an intensity exceeding 2.105 ions and 
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charge states ≥ 2 were selected from each MS spectrum for fragmentation by higher-
energy collisional dissociation. Spectra were collected at a resolution of 17,500 at 
200 m/z with a fixed first mass of 100 m/z, an automatic gain control target fixed at 
1.105 ions and a maximum injection time of 100 ms. Dynamic exclusion time was set 
to 60 s.  
 
The datasets were used for shotgun and TMPP data analyses  
 
Shotgun Data analysis. Shotgun analysis was carried out using MaxQuant (version 
1.6.0.16) (54). Raw data-derived peak lists were searched using the Andromeda 
search engine against an in-house database containing all Homo sapiens entries 
extracted from UniProtKB-SwissProt (release of 01/2016, 20 175 entries), common 
contaminants (119 entries) and the corresponding 20,294  reverse entries. The 
database was generated using the database toolbox from Mass Spectrometry Data 
Analysis (MSDA, publicly available from https://msda.unistra.fr)  (55). The precursor 
mass tolerance was set to 20 ppm for the first search and 4.5 ppm for the main 
search. The fragment ion mass tolerance was set to 20 ppm. Trypsin was chosen as 
the digestion enzyme and one missed cleavage was tolerated. 
Carbamidomethylation of cysteine residues was set as a fixed modification, and the 
oxidation of methionine residues and acetylation of protein N-termini as variable 
modifications. The minimum peptide length was set to seven amino acids. A 
maximum false discovery rate (FDR) of 1% was set at both the peptide and protein 
levels. Quantification, normalization and protein abundance estimation were 
performed using the MaxLFQ method implemented in MaxQuant(56). The option 
“match between runs” was enabled. Both modified and unmodified peptides 
(oxidation of methionine residues and acetylation of protein N-termini) were excluded 
from protein quantification. All other parameters were set as default. Proteins 
identified as “reversed”, “contaminants” or “only identified by site” and proteins 
identified with no unique peptide were discarded from the list of identified proteins. 
Protein identification was performed using internal peptides only and not the N-
terminal peptides, since they carried a TMPP label that could not be identified 
through this analysis. Mitochondrial proteins were extracted based on neXtProt gold 
and silver annotations for the GO term (GO:0005739) and the UniProt term (SL-
0173) for “Mitochondrion” (https://snorql.nextprot.org/). 
 
Statistical analysis of shotgun proteomics data.  Proteins with two or more missing 
values per injection triplicate were discarded. In each analysis, protein abundance 
was normalized to the sum of all protein abundances. Finally, the median of the 
injection triplicate data was calculated for each protein, and this value was used as 
the protein abundance for this biological point. This led to a dataset with one value 
per protein and biological point, so that the final dataset contained three values 
(biological replicates) per biological condition (control, rapamycin-treated, zinc-
treated). Pairwise comparisons of the mitochondrial protein abundances in the 
treated samples and the control samples were carried out using the Perseus 
package (version 1.5.5.3). The log2-transformed quantities were checked for 
normality distribution (Shapiro-Wilk test) and homoscedasticity (Bartlett test) in 
RStudio (version 1.0.136), then submitted to a Student’s t-test. Proteins with p ≤ 0.05 
were considered as variants. To account for the multiple testing issue, we used 
several approaches such as the Benjamini-Hochberg FDR(57), the sequential Fisher 
approach (58) and the sequential goodness of fit approach (59). Global analysis of 
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the shotgun data was performed using the PAST software (60).  
 
TMPP data analysis. Raw data were converted into mgf files using the MSConvert 
tool from ProteomeWizard (v3.0.6090; http://proteowizard.sourceforge.net/). The 
peak lists were searched using Mascot (version 2.5.1; Matrix Science, London, UK) 
against the previously described in-house database. The following parameters were 
applied: semiTrypsin as the digestion enzyme, one permitted missed cleavage per 
peptide, a mass tolerance of 5 ppm for the precursor ions and 0.07 Da for the 
peptide fragments, carbamidomethylation of cysteine residues as a fixed 
modification, and oxidation of methionine residues and light (+572.18 Da) and heavy 
(+581.21 Da) TMPP derivatization on any N-terminal amino acid or side chain of 
tyrosine and lysine residues as variable modifications. Mascot result files were 
loaded into Proline software (http://proline.profiproteomics.fr(61)) and proteins were 
validated on pretty rank equal to one, and a Mascot ion score ≥ 13. The N-terminal 
peptides were validated using the “dN-TOP Validation Tool” available at 
https://msda.unistra.fr (55), by confirming the identification of both the light and 
heavy labelled peptide forms and their chromatographic co-elution (11). 
 
Statistical analysis of TMPP data. For each analysis, light and heavy TMPP-labelled 
peptide abundances were summed and normalized to the sum of all measured 
abundances of TMPP-labelled peptides. The median of the injection triplicates 
measurements was calculated for each peptide. Then peptides were classified as 
transit peptides or degradation peptides. When a mitochondrial protein bears a 
transit peptide, it is first cleaved by the intermediate peptidase. Then 
aminopeptidases may act on the new N-terminus and remove a few amino acids(10), 
leading to the mature form(s) of the protein. Further protein cleavage is indicative of 
protein degradation. Transit peptides were therefore defined as the most upstream 
position experimentally observed, either from the present study or from the literature 
(11,12,62). Positions up to 10 aa downstream of this most upstream position were 
also classified as transit peptides, in order to take into account the aminopeptidase 
processing. More downstream positions observed were classified as degradation 
peptides .  The following ratio was calculated (Equation 1) for each condition: 
 
            
                                                   
                                                      
 
 (Eq. 1 
 
where “i” represents a TMPP-labelled peptide, “j” the corresponding protein, and “all 
internal peptides” refers to all peptides belonging to the protein quantified with the 
MaxQuant workflow. Finally, only TMPP-labelled peptides that showed no missing 
value for their corresponding internal peptide abundances and that showed a non-
null abundance value in the control condition were retained. This restriction was 
seen as relevant as we should detect the N-terminus in the control condition. 
Statistical analyses were carried out using a Wilcoxon rank sum test or a Wilcoxon 
signed rank test in RStudio (version 1.0.136) to evaluate the influence of rapamycin 
or zinc treatment on the N-terminal processing.  
 
For the assessment of N-terminal trimming, a ragging index was calculated and 
defined using Equation 2 : 
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 (Eq. 2) 
 
 
This index was tested using a Wilcoxon signed rank test for modulation by the  
treatments. 
 
For distal peptides, where null values can be expected, at least in the control samples, 
the test variable was defined using Equation 3  
 
           
           
 (Eq. 3) 
where Ri,j is defined in Eq. 1. This value was tested by a Wilcoxon signed-rank test for 
modulation by the rapamycin or zinc treatment. 
 
 
For the statistical analysis of the distal peptides, where null values can be expected, at 
least in the control samples, the test variable was defined as (Equation 4): 
                         
                                
 (Eq. 4) 
where Ri,j is defined in Eq. 1.  
This value was tested by a Wilcoxon signed-rank test for modulation by the rapamycin 
or zinc treatment.  
 
Complete LC-MS/MS datasets were deposited to the ProteomeXchange Consortium 
via the PRIDE partner repository with the dataset identifier PXD010220 for shotgun 
data and PXD010572 for TMPP data (63). 
 
Enzyme assays 
 
In order to compensate for different mitochondrial purity and/or yield issues that 
could have biased the proteomic results, enzyme assays were carried out on 
complete cell extracts. Briefly, cells were harvested, rinsed twice with PBS and 
resuspended in a 10-fold pellet volume of lysis buffer (10 mM Hepes-NaOH pH 7.5, 
2 mM MgCl2, 1 mM EGTA, 50 mM KCl, 0.1% (w/v) tetradecyldimethylammonio 
propane sulfonate [SB 3-14]). Cells were lysed by incubating on ice for 20 minutes 
with occasional vortexing. The suspension was then centrifuged at 1000 g for 5 
minutes, the supernatant collected, protein concentration determined by a dye-
binding assay (53). Extracts were aliquoted and stored at -80°C until use.  
Citrate synthase (CISY) activity was measured as described in (64), using liberation 
of coenzyme A and 5-5'-thio-bis-(2nitrobenzoic acid) (DTNB) reduction at 412 nm. 
Biphenyl hydrolase-like protein (BPHL) activity was measured through the 
homocysteine thiolactonase activity (65), using DTNB reduction. 
Succinate dehydrogenase (SDH) (66), D- and L-hydroxybutyrate dehydrogenase 
(D2HDH and L2HDH) (67), NAD-dependent isocitrate dehydrogenase (IDH) (68) and 
pyruvate dehydrogenase (PDH) (69) activities were all measured by the PMS-
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coupled iodonitrotetrazolium reduction method. Glutaminase (GLSK) activity was 
measured with a glutamate dehydrogenase-coupled assay (70). All results were 
converted into nmol substrate converted per min and mg protein, using the extinction 
coefficient of the final product.  
 
 
Results 
 
Modulation of the mitochondrial proteome by rapamycin and zinc 
 
A classical differential analysis using internal peptides was performed to investigate 
the effects of rapamycin and zinc on the mitochondrial proteome after a 24 hours 
treatment (Supplementary Tables 1 and 2).  Clustering analysis on all the 
experimental replicates (Figure 1) indicated that technical replicates are very closely 
related, validating our data reduction approach from the technical replicates. At a 
higher level, it appeared that treatment with rapamycin induced the strongest effects, 
while the effects of the treatment with zinc were less pronounced. 
Over 100 mitochondrially-annotated proteins were modulated by at least one of the 
treatments. A selection of these proteins is shown in Table 1 (the complete list of 
differentially expressed proteins being given in Supplementary Table 3). The 
expected false discovery rates for these proteins are provided for information in 
Supplementary Table 4.  
In order to gain more detailed insights into the physiological translation of the 
modulations found through this global proteomic screen, enzyme activity assays 
were performed. To alleviate possible artifacts due to variations in mitochondrial 
preparations purity, the enzymatic assays were carried out on total cell extracts. This 
prevented us from testing enzymes that have multiple locations (e.g. acyl coenzyme 
A ligases, nucleotide-modifying enzymes) or activities for which cytosolic and 
mitochondrial isoforms coexist (e.g. NADP-dependent isocitrate dehydrogenase or 
adenylate kinase). While this severely limited the number of enzymes that could be 
tested, clearcut results were obtained for glutaminase, D- and L-hydroxybutyrate 
dehydrogenase, NAD-dependent isocitrate dehydrogenase, succinate 
dehydrogenase, citrate synthase and BPHL as summarized in Table 2. Good 
agreement between the enzymatic assays and the proteomic results was observed 
for citrate synthase (CISY), succinate dehydrogenase (SDHA and SDHB) and L-
hydroxybutyrate dehydrogenase (L2HDH), moderate agreement was observed for 
D-hydroxybutyrate dehydrogenase (D2HDH) and glutaminase (GLSK), and poor 
agreement was seen for BPHL and NAD-dependent isocitrate dehydrogenase (IDH). 
In the case oh IDH, it should be noted that the amount of only one subunit (IDH3G) 
appeared to be modulated. As the complete active enzyme is a tetramer (2xIDH3A, 
IDH3B and IDH3G) (71), it is unsurprising that the enzymatic activity does not follow 
the trend given by only one of the subunits.  
In addition to these enzymes, we also tested the pyruvate dehydrogenase (PDH) 
activity. The PDH subunits did not appear in the list of modulated proteins, but PDH 
activity is regulated by phosphorylation (72) and both the kinase and the 
phosphatase subunits appeared in the list of modulated proteins, with opposite 
trends. These changes in the PDH phosphatases (PDP1 and PDPR) and PDH 
kinases (PDK1 and PDK3) amounts suggest a decrease in the PDH activity upon 
treatment by rapamycin or zinc, which was confirmed by the enzymatic assay (Table 
2).  
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Altogether, these results pointed to a decrease in the mitochondrial metabolism upon 
treatment by zinc or rapamycin. To investigate possible consequences of such a 
decrease on the mitochondrial function, we checked the mitochondrial 
transmembrane potential via a fluorescent dye accumulation assay. The 
fluorescence values (mean±standard deviation, normalized fluorescence units on  
independent biological triplicates) were 100±4 in the control samples, 98±9 in the 
rapamycin-treated samples, and 96±6 in the zinc-treated samples. None of these 
changes were statistically significant. As the fluorescence intensity depends on both 
the intrinsic activity of each mitochondrion and on the number of mitochondria, it can 
be reasonably inferred that neither treatment induced a major change in the number 
of mitochondria.  
Analysis of shotgun proteomic data indicated that both treatments induced 
alterations of the mitochondrial proteome, but no gross cellular dysfunction nor 
massive cell death was observed. Thus,  the dynamics of the mitochondrial protein 
processing system under moderate stress could be assessed.  
Indeed, two of the proteins identified as strongly decreased was the mitochondrial 
intermediate peptidase (MIPEP) and the beta (catalytic) subunit of the mitochondrial 
processing protease (MPPB), pointing to possible defects in the processing of 
mitochondrial proteins upon treatment with rapamycin or zinc. To investigate such 
effects, the shotgun proteomic study was combined with a N-terminomics 
investigation using the dN-TOP approach (11), which allows simultaneous and 
parallel analysis of internal and N-terminal peptides (Supplementary Table 8). We 
sorted the N-terminal peptides according to their positions as described in the 
methods section.  Upstream peptides were classified as possible transit/signal 
peptides (Supplementary Table 7). More downstream peptides were classified as 
peptides indicative of protein degradation (Supplementary Table 8).  
 
First and foremost, new, alternate N-termini were not detected following treatment 
with rapamycin or zinc. Despite the decrease in MIPEP and MPPB, the N-termini 
detected in the rapamycin- or zinc-treated samples were always similar to those 
detected in the control samples, indicating that the mitochondrial processing system 
is robust, at least under those conditions. Besides MIPEP, the processing system 
also includes aminopeptidases, which sometimes results into ragged ends. 
Evaluation of the quantitative ratio between the various N-terminal positions by a 
Wilcoxon signed rank test indicated that the trimming process was not significantly 
altered by the rapamycin treatment, although only twenty-two proteins with ragged 
ends at positions compatible with a transit peptide (i.e. between positions 10 and 
100) could be analyzed. Zinc, however, caused a small  but consistent and 
statistically significant decrease in N-terminal trimming (Figure 2 A-B). 
 
We then used the quantitative data to check whether treatment with rapamycin or 
zinc induced a quantitative alteration in the N-terminal processing. As the 
mitochondrial stressors used in this study did induce changes in the mitochondrial 
proteome as shown by the shotgun proteomics part of the study, the intensity of the 
N-terminal peptides signals alone were not sufficient to study the changes occurring 
in the processing system, and we had to compensate for the changes brought to 
protein amounts . To this purpose, we calculated for each protein and each point the 
ratio between the intensity of the TMPP-labelled peptide and the sum of all identified 
internal peptides belonging to the target protein. This ratio can be seen as an index 
of the properly processed protein form.  
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So for each protein, if there is only a change in the protein amount without any 
difference in the efficiency of the N-terminal processing, the signals for the N-
terminal peptides and for the internal peptides should change in parallel, leading to   
a theoretically constant N-terminal/internal peptides ratio. 
If there is an altered N-terminal processing, this may result into minor N-terminal 
peptides different from the canonical one, which may go undetected if they are too 
minor in abundance. This would however result in a decrease of the signal of the 
canonical peptide, and thus in a decrease of the TMPP/internal peptides ratio. In 
order to detect a general trend in the accurate processing of mitochondrial proteins 
without being biased by quantitative outliers, we performed a rank statistical analysis 
of this ratio by a Wilcoxon Signed Rank Test. This test revealed that rapamycin 
significantly affected the mitochondrial processing system (p<0.00001), whereas zinc  
did not (p=0.29) (Figure 2 C-D) . The same analysis performed on distal peptides, 
indicative of protein degradation, revealed that the TMPP/internal  peptides ratios 
were significantly higher for distal peptides (p<0.01 for both rapamycin and  zinc 
treatments), showing that these treatments promote protein degradation (Figure 2 E-
F).  
In these statistical tests, the test variable is compared to a random distribution to 
determine whether it differs from random or not. Such analyses cannot compare the 
measured effects of treatment with other induced cellular effects. To address this 
question, we used the fact that both mitochondrial and non-mitochondrial proteins 
are present in our analyses, and performed a Wilcoxon rank sum test using all 
proteins (mitochondrial and non-mitochondrial) with a labelled N-terminal peptide at 
a position between 1 and 100. The TMPP/internal peptides ratios were significantly 
lower for mitochondrial proteins compared to non-mitochondrial ones following 
rapamycin treatment (p<0.001), showing at least that the mitochondrial processing 
system is  more sensitive to rapamycin than other cellular processing systems (e.g. 
the signal peptidase). Zinc treatment caused a much less dramatic effect (p ≈ 0.08). 
(Figure 2 G-H).  
 
 
Discussion 
 
Most current N-terminomics approaches  focus on the analysis of terminal peptides 
(10,73,74), whereas the dN-TOP approach singles out by its ability to analyze within 
a single run both the N-terminal and internal peptides, at the expense of a 
requirement for free amino termini. This makes the method suitable for degradome 
and processome studies. In the present study, it enabled investigation of the 
changes in the N-terminal processing system following various treatments. Neither 
zinc nor rapamycin exposure caused  massive, detectable alterations of the 
mitochondrial proteins, such as new N-terminal positions, which is to be expected 
given the critical role of mitochondria in eukaryotic life. The mitochondrial 
transmembrane potential, and hence, mitochondrial function, were not affected by 
the treatments. From the results of fluorescence and shotgun analyses, we can 
conclude that the intrinsic activity of each mitochondrion, the number of mitochondria 
and the protein-processing system were unaffected by the treatments. However, the 
efficiency of protein processing may be altered in such sub-lethal stress, leading to 
minor errors which were not directly detected in the proteomic analysis. 
These minor alterations can be globally investigated using the multiplicity of the N-
terminomics data combined with statistical analyses. If the applied stress causes no 
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biological effects on the protein-processing system, observed variations should 
follow a random distribution. Our statistical analysis of the quantitative data showed 
that this was not the case, suggesting an overall reduction in the efficiency of the 
processing system.  
Interestingly, the N-terminal trimming process was slightly but significantly inhibited 
by zinc. The three mitochondrial  aminopeptidases known to date (MAP12, MAP2 
and XPP3) are all metalloproteases containing respectively cobalt for MAP12 (75) 
and manganese for MAP2 and XPP3 (76,77)) as metal cofactors, and are thus very 
likely to be directly inhibited by excess zinc, as previously described for other 
metalloproteases (78,79). This mechanism also probably applies to the mitochondrial 
processing protease, which is known to be a zinc metalloprotease (80), and has 
been described to be inhibited by excess zinc (81). 
 
A slight but significant change was also detected when distal N-termini were 
analyzed. In this case, an increase of the distal N-termini was detected after 
exposure to either zinc or rapamycin. However, the detection of cleaved proteins 
forms indicate that they were stable enough to accumulate and were immediately 
destroyed by the intramitochondrial proteases. Thus, our results can be correlated 
with the observed decrease in the amounts of the ClpP and Lon proteases upon zinc 
and rapamycin treatments (Table 1). Interestingly, several mitochondrial 
metalloproteases classified as quality control proteases (13)  were detected in our 
proteomic screen but did not exhibit significant quantitative changes upon zinc 
treatment, as shown in Supplementary Table 3 for the PREP, OMA1, SPG7, and  
AFG32 proteases. However, the zinc inhibition mechanism described above may 
apply to these proteases too and explain the increase in distal termini observed upon 
zinc treatment. 
 
Our data highlighted new players in the mitochondrial response to zinc or rapamycin 
exposure. 
Regarding zinc, citrate synthase appears as an important enzyme, in addition to 
ketoglutarate dehydrogenase (38). Citrate synthase active site contains two 
histidines (82,83), which are known to bind zinc with a high affinity (84) and lead 
sometimes to protein activation,as described for example for kallikrein 5 (85).  This 
hypothesis is further substantiated by the binding of citrate synthase to zinc (86). 
This may explain the observed decreased activity, and, through a zinc-induced 
destabilization mechanism, the observed decrease in amount of this protein.  
The observed concomitant decrease in  pyruvate dehydrogenase activity  may  
explain the protective roles of pyruvate and oxaloacetate (41). Increased 
concentrations of these two substrates of the citrate synthase and pyruvate 
dehydrogenase  may overcome the moderate decrease in the enzymes' activities,  
restoring normal mitochondrial function (41). 
In the same trend, the decrease in the two hydroxyglutarate dehydrogenase 
activities upon zinc treatment is also of interest, as these enzymes appear to be 
"metabolic repair" enzymes which degrade byproducts of isocitrate dehydrogenase 
(D-hydroxyglutarate, (87)) and malate dehydrogenase (L-hydroxyglutarate (88)) 
activities. The observed decrease in these activities following zinc exposure may 
contribute to the toxicity of zinc toward mitochondria.  
 
The effects of rapamycin on mitochondria were expected to be indirect, and our 
results support previously published data (47,49). Decrease in mitochondrial 
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metabolism was indicated by the decrease in the activity of the citrate cycle 
(revealed by the decreased activities of citrate synthase and pyruvate 
dehydrogenase). However, in contrast to results previously published on T 
lymphocytes (49), the activity changes that we observed in our macrophage system 
did not result into any gross alterations of the mitochondria such as a decreased 
transmembrane potential. Our study demonstrates that proteomics is able to detect 
moderate changes in cell and organelle systems before large physiological 
consequences occur.  
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Table 1: Selected mitochondrial proteins after the proteomic shotgun analysis 
 
Fasta headers UniProt ID 
Rapa / 
Control 
T-test 
Rapa 
Zn / 
Control T-test Zn 
Complex II subunits 
     Succ. Dehydrogenase sub.A† P31040 1.29 0.048 1.19 0.057 
Succ. Dehydrogenase sub.B P21912 1.20 0.0047 1.132 0.19 
Complex III* subunits 
     Complex III subunit 1 P31930 1.10 0.16 1.22 0.015 
Complex III subunit 2 P22695 1.08 0.17 1.23 0.012 
Complex III subunit 6 P07919 1.05 0.98 1.08 0.88 
Complex III subunit 7 P14927 1.02 0.88 1.18 0.54 
Complex III subunit 8 O14949 0.91 0.65 1.04 0.93 
Complex III subunit 9 Q9UDW1 0.87 0.37 0.78 0.21 
Complex V subunits  
     ATP synthase subunit alpha P25705 1.01 0.88 1.12 0.34 
ATP synthase subunit beta P06576 1.93 0.050 1.61 0.13 
ATP synthase subunit gamma P36542 0.94 0.84 1.03 0.82 
ATP synthase subunit delta P30049 2.25 0.0050 1.63 0.022 
ATP synthase subunit d O75947 1.10 0.49 1.18 0.36 
ATP synthase subunit e P56385 0.828 0.29 0.76 0.29 
ATP synthase subunit f P56134 0.90 0.51 1.14 0.50 
ATP synthase subunit g O75964 0.87 0.36 0.99 0.90 
ATP synthase subunit O P48047 0.96 0.85 1.14 0.59 
ATP synthase subunit s Q99766 1.01 0.99 1.03 0.98 
ATP synthase subunit 8 P03928 1.14 0.47 1.06 0.75 
ATP synthase coupling fact. 6 P18859 1.78 0.14 1.82 0.022 
ATP synth. assembly fact. 2 Q8N5M1 0.53 0.026 0.44 0.14 
Enzymes ** 
     Valacyclovir hydrolase Q86WA6 0.47 0.0033 0.60 0.028 
D-2 hydroxyglutarate DH Q8N465 0.51 0.029 1.01 0.89 
L-2 hydroxyglutarate DH Q9H9P8 0.82 0.040 0.95 0.62 
Pyruvate DH phosphatase 1 Q9P0J1 0.73 0.029 0.70 0.079 
Pyruvate DH phosphatase reg Q8NCN5 0.72 0.031 0.64 0.061 
Pyruvate DH kinase 1 Q15118 1.43 0.048 1.28 0.35 
Pyruvate DH kinase 3 Q15120 1.07 0.38 1.38 0.0061 
Isocitrate DH (NAD) sub. beta O43837 0.76 0.059 0.82 0.049 
Isocitrate DH (NAD) sub. alpha P50213 0.97 0.91 0.85 0.49 
Isocitrate DH  sub. gamma P51553 0.72 0.034 0.86 0.21 
Glutaminase O94925 0.48 0.0038 0.81 0.096 
Citrate synthase O75390 0.72 0.09 0.70 0.017 
Proteases 
     Lon protease homolog P36776 0.71 0.18 0.56 0.051 
Clp Protease catal. subunit Q16740 0.51 0.04 0.61 0.031 
Mito. Intermediate peptidase† Q99797 0.553 0.0017 0.65 0.011 
Mito. processing protease beta† O75439 0.64 0.079 0.69 0.045 
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Mito. processing protease alpha Q10713 0.80 0.563 0.85 0.691 
 
* complex III :  ubiquinol-cytochrome c reductase complex 
 
**  DH= dehydrogenase 
† : normalized peptide intensities for these proteins are provided in Supplementary Table 5 
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Table 2 : Mitochondrial enzyme activities 
 
 
Enzyme control rapamycin zinc 
ratio 
rapa/ 
ctrl 
ratio 
zinc/ 
ctrl 
Shotgun 
ratio 
rapa/ctrl 
Shotgun 
ratio 
zinc/ctrl 
    
 
 
  
glutaminase 196±35 152±16 121±8 0.77 0.62* 0.48 0.81 
L-hydroxyglutarate dehydrogenase 164±30 122±10 114±22 0.74 0.70* 0.82 0.95 
D-hydroxyglutarate dehydrogenase 137±23 109±11 102±13 0.80 0.75 0.51 1.01 
NAD-isocitrate dehydrogenase 276±11 270±27 219±40 0.98 0.79 ND ND 
succinate dehydrogenase 82±6 114±8 112±8 1.40** 1.37** >1.20 >1.13 
BPHL (Valacyclovir hydrolase) 842±81 677±72 790±56 0.80* 0.94 0.47 0.60 
citrate synthase 900±97 573±69 614±72 0.64** 0.68** 0.72 0.70 
pyruvate dehydrogenase 188±20 155±14 141±21 0.83* 0.75* NR NR 
 
 
All the activities are expressed in nmole substrate converted/min/mg total protein (mean±standard deviation). 
The experiments were carried out on total cell extracts (n=3, biological replicates). Statistical significance of the 
results in the heteroscedastic Student T test : * p<0.05 ; ** p<0.01. 
 
ND : not determined, as the enzyme is composed of several subunits 
 
NR : not relevant, as the pyruvate dehydrogenase activity is controlled by phosphorylation 
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Figure 1: Global analysis of the proteomic experiment by hierarchical clustering 
 
The clustering was calculated by the PAST software using a Paired group algorithm 
(UGPM) and an Euclidean similarity index. 
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Figure 2: Wilcoxon signed-rank test results (A to F) and Wilcoxon rank-sum test 
results (G, H). 
Box plots represent the ranking of the compared groups, while evaluating the 
influence of the treatments on the ragging process (A, rapamycin treatment; B, zinc 
treatment), on the mitochondrial processing system (C, rapamycin treatment; D, zinc 
treatment), on mitochondrial protein degradation (E, rapamycin treatment; F, zinc 
treatment) and on protein processing systems (G, rapamycin treatment; H, zinc 
treatment). Ratio values are plotted on the y-axes. For each group, dots represent 
the evaluated ratio value for N-terminal peptides. Peptides of proteins contained in 
Table 1, if present in the compared groups, are highlighted using colors. Tests are 
performed at a predefined significance level of p = 0.05. 
 
